| Literature DB >> 32181500 |
Tim Niehues1, Tuba Turul Özgür1, Marie Bickes2, Rebekka Waldmann3, Jennifer Schöning2, Jan Bräsen4, Christian Hagel5, Matthias Ballmaier6, Jan-Henning Klusmann7,8, Alexandra Niedermayer3, Ulrich Pannicke3, Anselm Enders9,10, Gregor Dückers1, Kathrin Siepermann1, Julyia Hempel2, Klaus Schwarz3,11, Dorothee Viemann2.
Abstract
AMPK (adenosine monophosphate-activated protein kinase) is phosphorylated (AMPK-P) in response to low energy through allosteric activation by Adenosine mono- or diphosphate (AMP/ADP). Folliculin (FLCN) and the FLCN-interacting proteins 1 and 2 (FNIP1, 2) modulate AMPK. FNIP1 deficiency patients have a AMPK-P gain of function phenotype with hypertrophic cardiomyopathy, Wolff-Parkinson-White pre-excitation syndrome, myopathy of skeletal muscles and combined immunodeficiency.Entities:
Keywords: B cell development; cardiomyopathy; immunodeficiency; metabolism; myopathy
Mesh:
Substances:
Year: 2020 PMID: 32181500 DOI: 10.1002/eji.201948504
Source DB: PubMed Journal: Eur J Immunol ISSN: 0014-2980 Impact factor: 5.532